secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001628280-24-033629
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70
--------------------------------------------------------------------------------

- Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).
- GAAP diluted EPS $0.88 (vs $1.33); adjusted diluted EPS $1.80 (vs $1.54), +16.4%.
- Acquired NAV-4694 (Alzheimer's), global rights to RM2 theranostic pair (prostate/breast), and two preclinical assets from Radiopharm Theranostics.
- FY 2024 revenue guidance reaffirmed $1.50-1.52B; adjusted EPS guidance lowered to $6.60-6.70 from $7.00-7.20 due to BD investments.
- CMS proposed OPPS rule improves separate payment for diagnostic radiopharmaceuticals like PYLARIFY in hospital outpatient setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/0001628280-24-033629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/lnth-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer